All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The results of this trial were presented by Maxime Chénard-Poirier from the Royal Marsden Hospital in London in an oral abstract session at ASCO 2017 Annual Meeting in Chicago, Illinois. This presentation was part of the ‘Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics’ session on Saturday June 4th, 2017.
CH5126766 is a first-in-class MEK inhibitor, with a long half-life (an average of 60 hours). Based on this extended half-life, dosing frequencies of two or three times weekly were studied in a dose escalation trial of 22 patients. However, the maximum tolerated dose and frequency was 4 mg two times per week. The most commonly reported adverse events (AEs) included rash, CK elevation, blurred vision, diarrhea, mucositis, fatigue and nausea. The most common grade 3 or higher toxicity was skin rash, which was managed with topical treatment.
This agent shows much promise for treatment of many malignancies, including myeloma, since approximately 20% of myeloma patients are positive for KRAS and NRAS mutations. In-vitro, MEK inhibitors are active against myeloma cell lines regardless of RAS status.
In summary, twice weekly scheduling is well-tolerated. Preliminary results suggest single agent MEK inhibition may have activity in relapsed/refractory multiple myeloma.
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox